Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

NCT05643534 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions

DRUG: Tenapanor 50 MG
DRUG: Tenapanor 25 mg bid
DRUG: Placebo

Sponsor

Ardelyx